Saiama Naheed Waqar MD

Thoracic Cancer

Associate Professor, Division of Oncology, Washington University School of Medicine

4921 Parkview Pl# DvSt. Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192

Dr. Waqar is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waqar's full profile Already have an account?

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2008 - 2011
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2008
Aga Khan Medical CollegeClass of 2001

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 2020 - 2029
MO State Medical License 2008 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR, Allscripts, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification Allscripts TouchWorks EHR (Complete), Allscripts, 2012, 2014-2017

Clinical Trials

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
COMPLETED
PHASE1, PHASE2
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
TERMINATED
PHASE2, PHASE3
Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite
WITHDRAWN
PHASE2

Publications & Presentations

PubMed

Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy.
Ayesha Hashmi, Jessica Linford, Pradeep S Chauhan, Kaushal Parikh, Malvika Pillai
Clinical Cancer Research. 2026-07-17
Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, Hossein Borghaei, D Ross Camidge
Journal of Clinical Oncology. 2026-06-03
Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901).
Melisa L Wong, Minji K Lee, Oudom Kour, Daniel Satele, Carolyn J Presley
Journal of the National Cancer Institute. 2026-05-20

Journal Articles

Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung Cancer
Saiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature

Lectures

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection—Reply
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018

Press Mentions

Who Is Most at Risk for Lung Cancer?November 15th, 2025
NCCN Clinical Practice Guidelines in Oncology: 2025 UpdatesMay 15th, 2025
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLCOctober 22nd, 2024